KIORA PHARMACEUTICALS INC — Director's Dealing 2018

Jul 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2018-07-10

Reporting Person: HANCOCK THOMAS (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-10	Stock Option (right to buy)	$0.57	A	50000	Acquired	2028-07-10	Common Stock (50000)	Direct

Footnotes

F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on July 10, 2019.